Global Search

Hide Filters

Showing 742 results

Clinical Trials / Apr 30, 2026

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Press release / Sep 19, 2019

AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1

New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate major milestone gainUpdated results from global…
Clinical Trials / Apr 30, 2026

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Press release / Apr 24, 2018

AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology

– A mean increase in CHOP-INTEND of 17.3 was observed at three months post gene therapy in SMA Type 1 U.S. pivotal trial – – All patients in the therapeutic dose cohort in the Phase 1 trial…
Clinical Trials / May 05, 2026

Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice
Press release / Apr 23, 2021

Novartis to initiate SMART Phase 3b global study of Zolgensma in children up to 21 kg, building on real-world experience

SMART study to extend data beyond patient population studied in clinical trials New clinical study to evaluate safety and efficacy of Zolgensma in children up to 21 kg, adding to real-world…
Press release / Mar 20, 2023

Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset

Children in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years post one-time intravenous infusionAll children (100%) in the presymptomatic intravenous…
Press release / Sep 02, 2019

Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings

Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients[1…
Press release / Sep 18, 2024

New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients

Nearly 90% of first-line Kesimpta patients had no disability progression independent of relapse activity (PIRA) for up to six years in an analysis of open-label ALITHIOS extension study1More than 80…
Press release / Jan 16, 2018

AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy

– Company to expand study of AVXS-101 into additional SMA populations including pre-symptomatic, older pediatric Type 2 and Type 3 SMA patients – – First patient dosed in Phase 1 trial of…

‹ Previous page
1
…
64
65
66
67
68
69
70
…
75
› Next page